Test Issue

April 2019

Volume 5, Issue 5

This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.

Table of Contents

April 2019 Issue

Perish to Publish: Repeated Episodes of Peer Rejection During the Publication Process

Friday, April 19th, 2019
In adults – sensitive adults, in particular – who consider themselves academics, repeated episodes of peer rejection can have serious emotional repercussions. We (David...

The Color of Blood and “Exohematology”

Friday, April 19th, 2019
Spilled blood’s brilliant red color has a rich symbolic history. The crimson color chemistry of porphyrin-bound iron ions led our ancestors to equate red...

April 2019 Issue

The Society Pages

Remembering Francesco Lo Coco, NYU Langone Health to Establish Center for Blood Cancers, and...

Friday, April 19th, 2019
Remembering Francesco Lo Coco (1955 – 2019)  Francesco Lo Coco, MD, a renowned leukemia researcher and pioneer of targeted therapy, passed away on March 3,...
ASH Directions

ASH Expands Global Initiative, Awards Research Award to Minority Scholar

Friday, April 19th, 2019
ASH Expands Global Initiative With Research Award for Hematologists Outside North America  The American Society of Hematology (ASH) Global Research Award was established in 2018...

April 2019 Issue

Test Post App

Friday, April 19th, 2019
Numbers don’t lie – except when people cause them to.  With an abundance of scientific research being presented and published, many health-care practitioners rely on...

Pulling Back the Curtain: Lukas Wartman, MD

Friday, April 19th, 2019
In this edition, Lukas Wartman, MD, discusses his decision to go into medicine and his life as a doctor and a patient. Hear more from...

Reader Beware: Interpreting Clinical Trial Data

Friday, April 19th, 2019
Numbers don’t lie – except when people cause them to.  With an abundance of scientific research being presented and published, many health-care practitioners rely on...

April 2019 Issue

You Make the Call

Reader Responses: Management of a patient with long-term B12 deficiency

Friday, April 19th, 2019
Here’s how readers responded to a You Make the Call question about 42-year-old female patient who has had very low B12 levels for at...
You Make the Call

Management of a patient with long-term B12 deficiency

Friday, April 19th, 2019
This month, Marilyn Telen, MD, discusses management of a patient with long-term B12 deficiency. And don't forget to check out next month's clinical dilemma - send...

April 2019 Issue

Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML

Friday, April 19th, 2019
For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
WIB_icon

Can a Virtual Benign Hematology Consult Improve Access to and Quality of Care?

Friday, April 19th, 2019
A multidisciplinary team of researchers developed a virtual benign hematology consultative service that can potentially reduce the time it takes a specialist to examine...

JULIET Analysis Finds Durable Responses With Tisagenlecleucel in DLBCL

Friday, April 19th, 2019
Half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded to tisagenlecleucel, and approximately two-thirds of responders are expected to remain...
WIB_icon

Carfilzomib Versus Bortezomib: Comparing Proteasome Inhibitors in Newly Diagnosed Myeloma

Friday, April 19th, 2019
Carfilzomib plus melphalan and prednisone (KMP) failed to improve survival outcomes for patients with newly diagnosed multiple myeloma (MM) compared with bortezomib plus melphalan...

Ibrutinib and Obinutuzumab Combo Granted Approval for CLL/SLL

Friday, April 19th, 2019
The U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib and obinutuzumab for the treatment of patients with treatment-naïve chronic lymphocytic leukemia/small...

FDA Approves Caplacizumab-yhdp for Acquired TTP

Friday, April 19th, 2019
Caplacizumab-yhdp, a bivalent anti–von Willebrand factor nanobody, was approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with...

Liquid Biopsy Test Cleared for Use in CML

Friday, April 19th, 2019
The U.S. Food and Drug Administration approved the QXDx AutoDG ddPCR System, a liquid biopsy test designed to precisely and reproducibly monitor molecular response...

New Treatment Approved for Hemophilia A

Friday, April 19th, 2019
The U.S. Food and Drug Administration approved turoctocog alfa pegol, an extended half-life factor VIII (FVIII) molecule formerly known as N8-GP, for the treatment...

FDA Warns Consumers About “Young Blood” Plasma Infusions

Friday, April 19th, 2019
Responding to the rising popularity of “anti-aging” plasma infusions from young adults, the U.S. Food and Drug Administration (FDA) has warned consumers that the...

Prognostic Impact of TP53 Mutations Varies in Patients With Complex Karyotype MDS

Friday, April 19th, 2019
In an analysis of mutation data from patients with complex karyotype myelodysplastic syndromes (CK-MDS), the presence of TP53 mutations conferred a poor prognosis, but...

April 2019 Issue

On location

A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?

Friday, April 19th, 2019
A study of patients with bone marrow failure (BMF) and short telomeres found that a conditioning regimen that eliminates radiation and DNA-alkylating agents led...
On location

Alemtuzumab Plus Myeloablative Conditioning Reduces Post-Transplant GVHD Risk

Friday, April 19th, 2019
For younger patients with sickle cell disease (SCD) who are eligible for a hematopoietic cell transplantation (HCT), adding alemtuzumab lowered the risk of graft-versus-host...

SHARE